HLS Therapeutics Inc. (HLS.TO) Research

HLS Therapeutics Inc. operates as a specialized pharmaceutical firm, concentrating on the acquisition and commercialization of medicinal products, primarily within the niche central nervous system (CNS) and cardiovascular (CV) sectors. Its reach extends across Canada, the United States, and international markets. The company's core product lineup includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsule formulation; and PERSERIS, an injectable risperidone product for treating schizophrenia. Additionally, HLS offers MyCare psychiatry laboratory assays and MyCare Insite tests for point-of-care therapeutic drug-level monitoring. Furthermore, the company possesses U.S. marketing privileges for Absorica, a commercial-stage dermatology solution, and Canadian rights for Trinomia, a cardiovascular therapeutic. It also manages a portfolio of royalty interests from four distinct healthcare products. Founded in 2018, HLS Therapeutics Inc. is based in Etobicoke, Canada.

Market snapshot

Symbol
HLS.TO
Price
$4.34
Day change
+1.17%
Market cap
$98.8M
P/E ratio
-9.80x
52-week range
0.001-5.765
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Next earnings
in 2 months

Peer companies

  • BioNxt Solutions Inc. (BNXT.CN)
  • Cardiol Therapeutics Inc. (CRDL.TO)
  • Grown Rogue International Inc. (GRIN.CN)
  • Helix BioPharma Corp. (HBP.TO)
  • Jushi Holdings Inc. (JUSH.CN)
  • Cannara Biotech Inc. (LOVE.V)
  • Planet 13 Holdings Inc. (PLTH.CN)
  • Quipt Home Medical Corp. (QIPT.TO)

Open HLS Therapeutics Inc. (HLS.TO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.